Loading...

PHAT PHATHOM PHARMACEUTICALS INC US FDA Inspections 8-K Filing

PHTH

PHT

PHATHOM PHARMACEUTICALS INC

(PHAT)

2025 8-K

Show Summary

Show Summary

Other Special Situation

Pre-Market Approval

Financial Statements

Director Appointment

Financial Results

Earnings Report

Financial Results

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Other Special Situation

Bylaws Amendment

Loan Agreement Amendment

FDA Acceptance of New Drug ...

Financial Results Announcement

FDA Approval for VOQUEZNA T...

FDA Stability Data Submission

Financial Results Announcement

Stock Option Exchange

Stock Option Exchange

FDA Acknowledges NDA Resubm...

Annual Meeting and Changes ...

Underwriting Agreement

Resubmission of New Drug Ap...

Financial Results Announcement

Regulatory Update

Financial Results Announcement

Positive Study Results for ...

External Links:

On June 6, 2025, Phathom Pharmaceuticals announced that the FDA approved their Citizen Petition from December 11, 2024, allowing for a 10-year exclusivity period for their drug VOQUEZNA through May 3, 2032.

AI Assistant

PHATHOM PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.